161 related articles for article (PubMed ID: 19258226)
1. [Hand-foot syndrome and sorafenib].
Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
[TBL] [Abstract][Full Text] [Related]
2. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
4. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
5. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Jain L; Gardner ER; Figg WD; Chernick MS; Kong HH
Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
9. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
10. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
Manchen E; Robert C; Porta C
J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
[TBL] [Abstract][Full Text] [Related]
11. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
12. Reader seeks clarification on hand-foot skin reaction.
Clark M
Clin J Oncol Nurs; 2008 Jun; 12(3):395; author reply 395. PubMed ID: 18564457
[No Abstract] [Full Text] [Related]
13. Interstitial granulomatous drug reaction to sorafenib.
Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
[No Abstract] [Full Text] [Related]
14. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
15. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
16. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
17. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
19. [Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome].
Delgado-Téllez L; Campos Fernández de Sevilla MA; Tutau F
Farm Hosp; 2009; 33(5):288-9. PubMed ID: 19775581
[No Abstract] [Full Text] [Related]
20. Erythema multiforme-like drug reaction to sorafenib.
Lewin J; Farley-Loftus R; Pomeranz MK
J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
